Thank you for the summary. Here are some additional points that I picked up from the call:
- Solvent prices have cooled in the past few months
- Prices of RM that are derived from lithium, iodine, sodium and phosphorus still at elevated levels
- Margin has bottomed out and can only improve from here. Oncology products to be margin accretive
- Participating in Januvia (sitagliptin) opportunity. Supplying to 2-3 customers. (Januvia global sales are $5 billion)
- Strategically increasing inventory of some key RM
- Cash on books - 478 cr
Key monitorable in the coming months, as rightly pointed out by @raghavbansal, is the possibility of a USFDA audit.
Subscribe To Our Free Newsletter |